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Clopidogrel as a prototype
As of  2007, PLAVIX (the original brand name of  Clopidogrel) 
had been the second top selling drug in the world and is, presently, 
prescribed and marketed in nearly 110 countries. Clopidogrel is 
currently the thienopyridine of  choice for dual antiplatelet thera-
py (in combination with aspirin) in patients with the full spectrum 
of  acute coronary syndrome and in patients undergoing percuta-
neous coronary intervention and stenting. In a plethora of  phar-
macogenomic studies on PLAVIX, it has been shown that Clopi-
dogrel is a prodrug that requires biotransformation to an active 
metabolite by CYP450 enzymes (mainly CYP2C19) and paraoxo-
nase 1 (PON-1). There is significant inter-individual variability in 
the response to PLAVIX, with up to 40% of  patients being classi-
fied as non-responders, poor responders or resistant to this drug. 
Pharmacogenomic information on PLAVIX reveals that genetic 
polymorphisms of  CYP enzymes (most commonly CYP2C19*2), 
PON-1 and also the ABCB 1 transporter contribute to variation 
in the response of  individual patients to PLAVIX. In March 2010, 
the FDA released a “Boxed Warning” on PLAVIX addressing the 
need for pharmacogenomic testing (for detecting CYP2C19 loss-
of-function polymorphisms) to identify patients’ altered PLAVIX 
metabolism, and thus their risk for a suboptimal clinical response 
to this drug. Based on an expanding database, and as an approach 
to the FDA boxed warning, the ACCF/AHA-convened writing 
committee developed an evidence-based guideline: “Recom-
mendations for Practice”, in July 2010. These documents were 
validated in France in October 2010 and the SmPC (Summary of  
Product Characteristics) of  PLAVIX was updated accordingly by 
the French regulatory agency (AFSSAPS).
Situation in France 
Generic Clopidogrel has been available on the market for a few 
years and is currently produced by several pharmaceutical compa-
nies all over the world. In France, for instance, generic versions 
of  Clopidogrel have been available since 2009, with some 21 
French generic products currently on the market. The majority 
of  generic versions, however, differ from the branded product, 
PLAVIX, by the salt formulation. Only the generic Clopidogrel 
marked by Zentiva, (the European generics business for the Sa-
nofi group), has the same formulation as PLAVIX. Although this 
structural difference may potientially have an impact on the phar-
macokinetics of  Clopidogrel, it does not have an effect on the 
pharmacogenetic conversion to active metabolites. Therefore, the 
same pharmacogenetic information as in the Plavix label should 
be present in the generic drug. While pharmacogenetic character-
istics of  PLAVIX have been well documented and are easily ac-
cessible, the relevant data for generic Clopidogrel is less available. 
In France, specifically, a recent survey carried out on the pharma-
cogenomic information included in the drug labels of  marketed 
French generic Clopidogrel products found that of  21, only 5 
generics provided the prescribers and patients with the applicable 
pharmacogenomic information. 
Call
The ESPT calls for a harmonized and consensus-based approach 
to an updatable drug labeling of  generic versions for pharmacog-
enomic information, as is the case for the original drug. This re-
quirement is, undoubtedly, not limited to Clopidogrel and should 
be extrapolated to all medications which are marketed as both 
branded and generic versions. 
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